查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1678787

全球臨床實驗室儀器市場 - 2025 至 2033 年

Global Clinical Laboratory Instruments Market - 2025-2033
出版日期: | 出版商: DataM Intelligence | 英文 176 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

2024 年全球臨床實驗室儀器市場規模達到 485.5 億美元，預計到 2033 年將達到 916.1 億美元，2025-2033 年預測期內的複合年成長率為 7.4%。

臨床實驗室儀器是醫學實驗室用來進行各種測試以有助於診斷、監測和治療各種疾病的重要工具。這些儀器涵蓋範圍廣泛，包括血液學分析儀、臨床化學分析儀、免疫分析儀、顯微鏡和分子診斷設備。它們執行血液檢測、組織分析以及病原體或特定生物標記的檢測等關鍵功能。

市場動態：

促進因素與約束因素

不斷進步的技術

預計在預測期內，不斷進步的技術將透過提高診斷測試的效率、準確性和速度，大大推動臨床實驗室儀器市場的發展。自動化、人工智慧 (AI) 整合、次世代定序 (NGS) 和即時診斷 (POC) 設備等創新正在徹底改變實驗室運作。

此外，分子診斷和基因檢測的進步使得各種疾病能夠更早發現和個人化治療，從而推動了對專用儀器的需求。隨著技術的不斷進步，臨床實驗室的效率越來越高，從而增加了先進儀器的採用，從而推動了臨床實驗室儀器市場的成長。

例如，2024 年 6 月，HORIBA 擴大了其屢獲殊榮的緊湊型血液學儀器系列，推出了搭載紅血球沉降率 (ESR) 的新型號。新型 Yumizen H550E（自動裝填器）、H500E CT（閉管）和 Yumizen H500E OT（開管）可在 60 秒內提供全血 CBC/DIFF 與 ESR 結果的綜合檢測，為這些儀器原本就很廣泛的功能添加了全面的炎症疾病評估功能。

先進臨床實驗室儀器價格昂貴

先進臨床實驗室儀器的高成本可能會限制資源匱乏地區的醫療機構使用，從而阻礙市場發展，因為這些地區的醫療機構可能沒有財力投資昂貴的設備。這導致預算受限的地區採用尖端技術的速度較慢，尤其是公立醫院或較小的私人診所。

目錄

第 1 章：方法與範圍

第 2 章：定義與概述

第 3 章：執行摘要

第 4 章：動態

  • 影響因素
    • 驅動程式
      • 技術進步
      • 增加醫療基礎建設投資
    • 限制
      • 先進設備成本高昂
      • 維護和校準的複雜性
    • 機會
      • 對即時診斷（POC）的需求不斷成長
    • 影響分析

第5章：產業分析

  • 市場領導者和先驅者
  • 新興先鋒和傑出參與者
  • 擁有最大銷售品牌的成熟領導者
  • 擁有成熟產品的市場領導者
  • CXO 觀點
  • 最新進展與突破
  • 案例研究/正在進行的研究
  • 監管和報銷情況
  • 北美洲
  • 歐洲
  • 亞太地區
  • 拉丁美洲
  • 中東和非洲
  • 波特五力分析
  • 供應鏈分析
  • 專利分析
  • SWOT 分析
  • 未滿足的需求和差距
  • 市場進入和擴張的推薦策略
  • 情境分析：最佳情況、基本情況和最壞情況預測
  • 定價分析和價格動態
  • 關鍵意見領袖

第 6 章：按類型

  • 自動化
  • 半自動化
  • 手動的

第 7 章：按產品類型

  • 臨床化學儀器
  • 血液學分析儀
  • 免疫分析儀器
  • 微生物學儀器
  • 分子診斷儀器
  • 血氣及電解質分析儀
  • 照護端 (POC) 設備
  • 其他

第 8 章：按最終用戶

  • 醫院
  • 診斷實驗室
  • 學術及研究機構
  • 診所及門診手術中心

第9章：按地區

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 西班牙
    • 義大利
    • 歐洲其他地區
  • 南美洲
    • 巴西
    • 阿根廷
    • 南美洲其他地區
  • 亞太
    • 中國
    • 印度
    • 日本
    • 韓國
    • 亞太其他地區
  • 中東和非洲

第 10 章：競爭格局

  • 競爭格局
  • 市場定位/佔有率分析
  • 併購分析

第 11 章：公司簡介

  • Beckman Coulter, Inc.
    • 公司概況
    • 產品組合
      • 產品描述
      • 產品關鍵績效指標 (KPI)
      • 歷史和預測產品銷售量
      • 產品銷售量
    • 財務概覽
      • 公司收入
      • 地區收入佔有率
      • 收入預測
    • 主要進展
      • 合併與收購
      • 關鍵產品開發活動
      • 監管部門批准等
    • SWOT 分析
  • Thermo Fisher Scientific Inc.
  • Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
  • Siemens Healthineers AG
  • bioMerieux
  • Leica Microsystems
  • Abbott Laboratories
  • Roche Diagnostics
  • Transasia Bio-Medicals
  • Labtron Equipment Ltd.

第 12 章：附錄

簡介目錄
Product Code: LE9280

The global clinical laboratory instruments market reached US$ 48.55 billion in 2024 and is expected to reach US$ 91.61 billion by 2033, growing at a CAGR of 7.4% during the forecast period 2025-2033.

Clinical laboratory instruments are essential tools used in medical laboratories to conduct a wide range of tests that help in diagnosing, monitoring, and treating various diseases. These instruments encompass a broad spectrum of devices, including hematology analyzers, clinical chemistry analyzers, immunoassay analyzers, microscopes, and molecular diagnostic equipment. They perform critical functions such as blood testing, tissue analysis, and the detection of pathogens or specific biomarkers.

Market Dynamics: Drivers & Restraints

Rising Technological Advancements

Rising technological advancements are expected to significantly drive the clinical laboratory instruments market over the forecast period by improving the efficiency, accuracy and speed of diagnostic testing. Innovations such as automation, artificial intelligence (AI) integration, next-generation sequencing (NGS) and point-of-care (POC) devices are revolutionizing laboratory operations.

Additionally, advancements in molecular diagnostics and genetic testing are enabling earlier detection and personalized treatment for various diseases, driving demand for specialized instruments. With continuous improvements in technology, clinical laboratories are becoming more efficient, which in turn increases the adoption of advanced instruments, thereby fueling the growth of the clinical laboratory instruments market.

For instance, in June 2024, HORIBA expanded its award-winning compact hematology instrument range with the launch of new models with the Erythrocyte Sedimentation Rate (ESR) on board. The new Yumizen H550E (autoloader), H500E CT (closed tube), and Yumizen H500E OT (open tube) offer combined testing for CBC/DIFF with ESR results from whole blood in 60 seconds, adding a comprehensive profile for inflammatory disease assessment to the instruments' already extensive functionality.

High Costs of Advanced Clinical Laboratory Instruments

The high costs of advanced clinical laboratory instruments can hinder the market by limiting access in low-resource regions, where healthcare facilities may not have the financial capacity to invest in expensive equipment. This leads to slower adoption of cutting-edge technologies in areas with budget constraints, particularly in public hospitals or smaller private clinics.

Segment Analysis

The global clinical laboratory instruments market is segmented based on the type, product type, end-user and region.

Clinical chemistry instruments in the product type segment are expected to dominate the clinical laboratory instruments market with the highest market share.

The clinical chemistry instruments segment is expected to dominate the clinical laboratory instruments market due to their broad application in routine diagnostics and the growing prevalence of chronic diseases like diabetes, cardiovascular conditions, and kidney disorders. These instruments are essential for testing a wide range of substances such as glucose, cholesterol, proteins, and electrolytes, making them indispensable in diagnosing and monitoring various health conditions.

Additionally, technological advancements in automation have significantly improved the speed, accuracy, and efficiency of clinical chemistry analyzers, enabling high-throughput testing, reducing human error, and lowering operational costs.

For instance, Beckman Coulter Diagnostics will unveil its new DxC 500 AU Chemistry Analyzer, an automated clinical chemistry analyzer. The DxC 500 AU Chemistry Analyzer is one of several recent Beckman Coulter solutions designed to address the complete needs of healthcare systems that are looking to complement central hub laboratories by advancing the technology and capabilities of satellite and independent hospital laboratories. This makes clinical chemistry instruments vital in both high-volume hospital settings and smaller laboratories, ensuring their dominance in the market.

Geographical Analysis

North America is expected to dominate the clinical laboratory instruments market with highest market share

North America is expected to dominate the clinical laboratory instruments market due to its advanced healthcare infrastructure, strong presence of leading manufacturers, and substantial investments in healthcare. The region benefits from a high demand for diagnostic testing driven by the aging population, rising incidence of chronic diseases, and a focus on personalized medicine.

Technological advancements, including the adoption of molecular diagnostics, automated systems, and point-of-care devices, further bolster market growth. The robust regulatory framework, including FDA approvals, ensures high-quality standards for clinical laboratory instruments, while the region's strong research ecosystem, including top academic and clinical research institutions, drives continuous innovation.

For instance, in March 2023, PerkinElmer's Oxford Immunotec received the U.S. FDA approval for two additional cell isolation instruments, the Auto-Pure 24 and Auto-Pure 20B, for use with its T-Cell Select reagent kit in the T-SPOT.TB test workflow. All these factors combined ensure North America's continued dominance in the clinical laboratory instruments market.

Competitive Landscape

The global market players in the clinical laboratory instruments market are Beckman Coulter, Inc., Thermo Fisher Scientific Inc., Shenzhen Mindray Bio-Medical Electronics Co., Ltd., Siemens Healthineers AG, bioMerieux, Leica Microsystems, Abbott Laboratories, Roche Diagnostics, Transasia Bio-Medicals and Labtron Equipment Ltd., among others.

Key Developments

  • In April 2023, Waters Corporation unveiled its next-generation Xevo TQ Absolute IVD mass spectrometer, expanding its family of MassTrak IVD LC-MS/MS Systems for clinical diagnostic applications.
  • In June 2024, Thermo Fisher Scientific introduced a new mass spectrometry platform, in addition to several updates to existing products at the American Society for Mass Spectrometry (ASMS) conference in Anaheim.

Why Purchase the Report?

  • Pipeline & Innovations: Reviews ongoing clinical trials, and product pipelines, and forecasts upcoming pharmaceutical advancements.
  • Type Performance & Market Positioning: Analyzes product performance, market positioning, and growth potential to optimize strategies.
  • Real-World Evidence: Integrates patient feedback and data into product development for improved outcomes.
  • Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
  • Market Updates & Industry Changes: Covers recent regulatory changes, new policies, and emerging technologies.
  • Competitive Strategies: Analyzes competitor strategies, market share, and emerging players.
  • Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
  • Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
  • Regional Growth & Investment: Highlights high-growth regions and investment opportunities.
  • Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient Type delivery.
  • Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
  • Post-market Surveillance: Uses post-market data to enhance product safety and access.
  • Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.

The global clinical laboratory instruments market report delivers a detailed analysis with 45 key tables, more than 46 visually impactful figures, and 176 pages of expert insights, providing a complete view of the market landscape.

Target Audience 2024

  • Manufacturers: Pharmaceutical, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
  • Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
  • Technology & Innovation: R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
  • Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
  • Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
  • Supply Chain: Distribution and Supply Chain Managers.
  • Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
  • Academic & Research: Academic Institutions.

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by Type
  • 3.2. Snippet by Product Type
  • 3.3. Snippet by End-User
  • 3.4. Snippet by Region

4. Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Technological Advancements
      • 4.1.1.2. Increased Investment in Healthcare Infrastructure
    • 4.1.2. Restraints
      • 4.1.2.1. High Costs of Advanced Equipment
      • 4.1.2.2. Complexity of Maintenance and Calibration
    • 4.1.3. Opportunities
      • 4.1.3.1. Increasing Demand for Point-of-Care (POC) Diagnostics
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Market Leaders and Pioneers
  • 5.2. Emerging Pioneers and Prominent Players
  • 5.3. Established leaders with largest selling Brand
  • 5.4. Market leaders with established Product
  • 5.5. CXO Perspectives
  • 5.6. Latest Developments and Breakthroughs
  • 5.7. Case Studies/Ongoing Research
  • 5.8. Regulatory and Reimbursement Landscape
  • 5.9. North America
  • 5.10. Europe
  • 5.11. Asia Pacific
  • 5.12. Latin America
  • 5.13. Middle East & Africa
  • 5.14. Porter's Five Force Analysis
  • 5.15. Supply Chain Analysis
  • 5.16. Patent Analysis
  • 5.17. SWOT Analysis
  • 5.18. Unmet Needs and Gaps
  • 5.19. Recommended Strategies for Market Entry and Expansion
  • 5.20. Scenario Analysis: Best-Case, Base-Case, and Worst-Case Forecasts
  • 5.21. Pricing Analysis and Price Dynamics
  • 5.22. Key Opinion Leaders

6. By Type

  • 6.1. Introduction
    • 6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 6.1.2. Market Attractiveness Index, By Type
  • 6.2. Automated*
    • 6.2.1. Introduction
    • 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 6.3. Semi-automated
  • 6.4. Manual

7. By Product Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 7.1.2. Market Attractiveness Index, By Product Type
  • 7.2. Clinical Chemistry Instruments*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 7.3. Hematology Analyzers
  • 7.4. Immunoassay Instruments
  • 7.5. Microbiology Instruments
  • 7.6. Molecular Diagnostics Instruments
  • 7.7. Blood Gas & Electrolyte Analyzers
  • 7.8. Point-of-Care (POC) Devices
  • 7.9. Others

8. By End-User

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 8.1.2. Market Attractiveness Index, By Application
  • 8.2. Hospitals*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 8.3. Diagnostic Laboratories
  • 8.4. Academic & Research Institutes
  • 8.5. Clinics & Ambulatory Surgical Centers

9. By Region

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 9.1.2. Market Attractiveness Index, By Region
  • 9.2. North America
    • 9.2.1. Introduction
    • 9.2.2. Key Region-Specific Dynamics
    • 9.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 9.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 9.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 9.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 9.2.6.1. U.S.
      • 9.2.6.2. Canada
      • 9.2.6.3. Mexico
  • 9.3. Europe
    • 9.3.1. Introduction
    • 9.3.2. Key Region-Specific Dynamics
    • 9.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 9.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 9.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 9.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 9.3.6.1. Germany
      • 9.3.6.2. U.K.
      • 9.3.6.3. France
      • 9.3.6.4. Spain
      • 9.3.6.5. Italy
      • 9.3.6.6. Rest of Europe
  • 9.4. South America
    • 9.4.1. Introduction
    • 9.4.2. Key Region-Specific Dynamics
    • 9.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 9.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 9.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 9.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 9.4.6.1. Brazil
      • 9.4.6.2. Argentina
      • 9.4.6.3. Rest of South America
  • 9.5. Asia-Pacific
    • 9.5.1. Introduction
    • 9.5.2. Key Region-Specific Dynamics
    • 9.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 9.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 9.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 9.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 9.5.6.1. China
      • 9.5.6.2. India
      • 9.5.6.3. Japan
      • 9.5.6.4. South Korea
      • 9.5.6.5. Rest of Asia-Pacific
  • 9.6. Middle East and Africa
    • 9.6.1. Introduction
    • 9.6.2. Key Region-Specific Dynamics
    • 9.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 9.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 9.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

10. Competitive Landscape

  • 10.1. Competitive Scenario
  • 10.2. Market Positioning/Share Analysis
  • 10.3. Mergers and Acquisitions Analysis

11. Company Profiles

  • 11.1. Beckman Coulter, Inc.*
    • 11.1.1. Company Overview
    • 11.1.2. Product Portfolio
      • 11.1.2.1. Product Description
      • 11.1.2.2. Product Key Performance Indicators (KPIs)
      • 11.1.2.3. Historic and Forecasted Product Sales
      • 11.1.2.4. Product Sales Volume
    • 11.1.3. Financial Overview
      • 11.1.3.1. Company Revenue's
      • 11.1.3.2. Geographical Revenue Shares
      • 11.1.3.3. Revenue Forecasts
    • 11.1.4. Key Developments
      • 11.1.4.1. Mergers & Acquisitions
      • 11.1.4.2. Key Product Development Activities
      • 11.1.4.3. Regulatory Approvals etc.
    • 11.1.5. SWOT Analysis
  • 11.2. Thermo Fisher Scientific Inc.
  • 11.3. Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
  • 11.4. Siemens Healthineers AG
  • 11.5. bioMerieux
  • 11.6. Leica Microsystems
  • 11.7. Abbott Laboratories
  • 11.8. Roche Diagnostics
  • 11.9. Transasia Bio-Medicals
  • 11.10. Labtron Equipment Ltd.

LIST NOT EXHAUSTIVE

12. Appendix

  • 12.1. About Us and Services
  • 12.2. Contact Us